Arcus Biosciences
RCUS
24.52
+0.24
+0.99%
Arcus Biosciences
US · RCUS
#2467 by market cap
Listed 2018
24.52
+0.24
+0.99%
Live - 5344 symbols - heartbeat 409s ago
· 2026-10-07 19:54
After-hours
24.52
0.00%
- Market cap
- 3.12B
- P/E (TTM)i
- -6.22
- P/Bi
- 6.73
- EPSi
- -3.29
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on RCUS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.78, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -4.26% YoY
Margins
- Operating margin
- -156.28%
- Net margin
- -142.92%
Key ratios & quality
- Enterprise valuei
- 2.25B
- Altman Z-Scorei
- 1.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.35M | 15.00M | 78.00M | 383.00M | 112.00M | 117.00M | 258.00M | 247.00M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 13.57M | 25.23M | 43.00M | 72.00M | 104.00M | 117.00M | 120.00M | 110.00M |
| Research & development | 49.65M | 78.48M | 159.00M | 257.00M | 288.00M | 340.00M | 448.00M | 523.00M |
| Operating profit | -54.86M | -88.71M | -124.00M | 54.00M | -280.00M | -340.00M | -310.00M | -386.00M |
| Pretax profit | -49.59M | -84.71M | -123.00M | 55.00M | -266.00M | -301.00M | -282.00M | -353.00M |
| Tax | -- | 0 | 0 | 2.00M | 1.00M | 6.00M | 1.00M | 0 |
| Net profit | -49.59M | -84.71M | -123.00M | 53.00M | -267.00M | -307.00M | -283.00M | -353.00M |
| Basic EPS | -1 | -2 | -2 | 1 | -4 | -4 | -3 | -3 |
| Diluted EPS | -1.43 | -1.93 | -2.24 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 28.00M | 160.00M | 26.00M | 33.00M | 17.00M | 41.00M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 28.00M | 29.00M | 27.00M | 26.00M | 29.00M | 24.00M |
| Research & development | 122.00M | 139.00M | 141.00M | 121.00M | 122.00M | 113.00M |
| Operating profit | -122.00M | -8.00M | -142.00M | -114.00M | -134.00M | -96.00M |
| Pretax profit | -112.00M | 0 | -135.00M | -106.00M | -128.00M | -91.00M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -112.00M | 0 | -135.00M | -106.00M | -128.00M | -91.00M |
| Basic EPS | -1 | 0 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.14 | 0.00 | -1.27 | -0.89 | -1.02 | -0.72 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 258.95M | 192.71M | 735.82M | 1.26B | 1.07B | 831.00M | 1.02B | 1.01B |
| Cash & ST investments | 256.54M | 188.27M | 728.65M | 499.00M | 1.01B | 759.00M | 978.00M | 981.00M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 274.93M | 203.11M | 772.29M | 1.59B | 1.35B | 1.10B | 1.15B | 1.14B |
| Total current liabilities | 16.94M | 22.71M | 121.67M | 166.00M | 193.00M | 184.00M | 226.00M | 231.00M |
| Short-term debt | -- | -- | -- | -- | 3.00M | 11.00M | 12.00M | 13.00M |
| Long-term debt | -- | -- | -- | -- | -- | -- | 48.00M | 99.00M |
| Total liabilities | 39,983,000.00 | 39,268,000.00 | 269,988,000.00 | 750,000,000.00 | 688,000,000.00 | 633,000,000.00 | 665,000,000.00 | 508,000,000.00 |
| Total equity | 234.94M | 163.84M | 502.30M | 842.00M | 657.00M | 462.00M | 485.00M | 631.00M |
| Retained earnings | -122.83M | -205.33M | -328.18M | -275.00M | -542.00M | -849.00M | -1.13B | -1.49B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.03B | 946.00M | 857.00M | 1.01B | 844.00M | 756.00M |
| Cash & ST investments | 997.00M | 911.00M | 831.00M | 981.00M | 822.00M | 702.00M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.16B | 1.08B | 974.00M | 1.14B | 997.00M | 924.00M |
| Total current liabilities | 192.00M | 210.00M | 235.00M | 231.00M | 209.00M | 198.00M |
| Short-term debt | 12.00M | 12.00M | 13.00M | 13.00M | 13.00M | 13.00M |
| Long-term debt | 48.00M | 97.00M | 98.00M | 99.00M | 100.00M | 101.00M |
| Total liabilities | 625,000,000.00 | 526,000,000.00 | 538,000,000.00 | 508,000,000.00 | 473,000,000.00 | 460,000,000.00 |
| Total equity | 531.00M | 549.00M | 436.00M | 631.00M | 524.00M | 464.00M |
| Retained earnings | -1.24B | -1.24B | -1.38B | -1.49B | -1.61B | -1.70B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -43.00M | -73.46M | 111.00M | -256.00M | 438.00M | -306.00M | -170.00M | -482.00M |
| Depreciation & amortization | 3.66M | 3.58M | 3.00M | 4.00M | 6.00M | 8.00M | 10.00M | 10.00M |
| Free cash flow | -46.74M | -75.39M | 108.00M | -282.00M | 432.00M | -330.00M | -176.00M | -484.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 125.11M | -94.00K | 434.00M | 220.00M | 0 | 25.00M | 228.00M | 429.00M |
| Ending cash balance | 71.27M | 58.14M | 174.00M | 151.00M | 209.00M | 130.00M | 153.00M | 225.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -132.00M | -133.00M | -97.00M | -120.00M | -138.00M | -119.00M |
| Depreciation & amortization | 3.00M | 2.00M | 2.00M | 3.00M | 2.00M | 3.00M |
| Free cash flow | -133.00M | -133.00M | -97.00M | -121.00M | -138.00M | -119.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 142.00M | 0 | 8.00M | 279.00M | 0 | 0 |
| Ending cash balance | 195.00M | 251.00M | 241.00M | 225.00M | 204.00M | 153.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -25.51 | -42.48 | -36.89 | 7.86 | -35.64 | -54.87 | -59.77 | -63.26 |
| ROA %i | -21.31 | -35.44 | -25.19 | 4.47 | -18.18 | -25.16 | -25.21 | -30.84 |
| ROIC %i | -28.04 | -45.09 | -35.67 | 7.11 | -37.11 | -59.21 | -60.21 | -59.93 |
| 5-year avg ROE %i | -- | -- | -- | -- | -33.63 | -32.40 | -35.86 | -41.13 |
| EBIT margin %i | -656.76 | -591.39 | -160.27 | 14.34 | -235.71 | -255.56 | -108.14 | -139.68 |
| FCF / sales %i | -- | -- | 139.47 | -- | 380.36 | -- | -- | -- |
| Current ratioi | 15.29 | 8.49 | 6.05 | 7.60 | 5.53 | 4.52 | 4.50 | 4.36 |
| Quick ratioi | 15.15 | 8.31 | 6.00 | 7.51 | 5.45 | 4.35 | 4.44 | 4.32 |
| Debt / assetsi | -- | 0.00 | 1.97 | -- | 0.22 | 1.00 | 5.22 | 9.83 |
| LT debt / equityi | -- | -- | 3.03 | -- | -- | -- | 9.90 | 15.69 |
| Interest coveragei | -- | -- | -- | 211.17 | -132.00 | -149.50 | -69.75 | -43.13 |
| Revenue CAGR (3Y) %i | -- | -- | 280.76 | 257.92 | 95.45 | 14.47 | -12.34 | 30.16 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -63.17 | -50.34 | -68.13 | -63.26 | -69.95 | -90.82 |
| ROA %i | -31.93 | -26.36 | -30.64 | -30.84 | -34.28 | -46.02 |
| ROIC %i | -62.98 | -47.16 | -63.02 | -59.93 | -64.82 | -78.64 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -274.47 | -111.45 | -138.75 | -139.68 | -152.12 | -383.76 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.37 | 4.50 | 3.65 | 4.36 | 4.04 | 3.82 |
| Quick ratioi | 5.30 | 4.43 | 3.60 | 4.32 | 3.97 | 3.75 |
| Debt / assetsi | 5.19 | 10.14 | 11.40 | 9.83 | 11.33 | 12.34 |
| LT debt / equityi | 9.04 | 17.67 | 22.48 | 15.69 | 19.08 | 21.77 |
| Interest coveragei | -96.75 | -48.67 | -41.63 | -43.13 | -35.90 | -40.82 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing and commercializing highly differentiated therapies that have a meaningful impact100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.